References
- Eberhardt A, Madycki G, Hendiger W. Staszkiewicz W and Lewszuk A: elasticity of the carotid artery walls as a prognostic factor for the occurrence of restenosis after a surgery for internal carotid artery stenosis. Kardiol Pol. 2015;73:352–359.
- Schaftenaar F, Frodermann V, Kuiper J. Kuiper J and Lutgens E: atherosclerosis: the interplay between lipids and immune cells. Curr Opin Lipidol. 2016;27:209–215.
- Wu MY, Li CJ, Hou MF, et al. New insights into the role of inflammation in the pathogenesis of atherosclerosis. Int J Mol Sci. 201718.
- Atzeni F, Sarzi-Puttini P, Bevilacqua M. Calcium deposition and associated chronic diseases (atherosclerosis, diffuse idiopathic skeletal hyperostosis, and others). Rheum Dis Clin North Am. 2006;32:413–426, viii.
- Moss JW, Ramji DP. Nutraceutical therapies for atherosclerosis. Nat Rev Cardiol. 2016;13:513–532.
- Shin YJ, Lee JH, Yoo JY, et al. Clinical significance of evaluating coronary atherosclerosis in adult patients with hypertrophic cardiomyopathy who have chest pain. Eur Radiol. 2019;29:4593–4602.
- Berenson GS, Srinivasan SR, Freedman DS, et al. Atherosclerosis and its evolution in childhood. Am J Med Sci. 1987;294:429–440.
- Juonala M, Ellul S, Lawlor DA, et al. A cross-cohort study examining the associations of metabolomic profile and subclinical atherosclerosis in children and their parents: the child health checkpoint study and avon longitudinal study of parents and children. J Am Heart Assoc. 2019;8:e011852.
- Lechner K, von Schacky C, McKenzie AL, et al. Lifestyle factors and high-risk atherosclerosis: pathways and mechanisms beyond traditional risk factors. Eur J Prev Cardiol. 2020;27:394–406.
- Leong XF. Ng CY and Jaarin K: animal models in cardiovascular research: hypertension and atherosclerosis. Biomed Res Int. 2015;528757:2015.
- Poznyak A, Grechko AV, Poggio P, et al. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020 21.
- Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5: 56.
- Loehr LR, Rosamond WD, Chang PP. Heart failure incidence and survival (from the atherosclerosis risk in communities study). Am J Cardiol. 2008;101:1016–1022.
- Bohr AH, Fuhlbrigge RC, Pedersen FK, et al. Premature subclinical atherosclerosis in children and young adults with juvenile idiopathic arthritis. A review considering preventive measures. Pediatr Rheumatol Online J. 2016;14:3.
- Zhu YR, Jiang XX, Zhang DM. Critical regulation of atherosclerosis by the KCa3.1 channel and the retargeting of this therapeutic target in in-stent neoatherosclerosis. J Mol Med (Berl). 2019;97:1219–1229.
- Xu J, Lu X, Shi G-P. Vasa vasorum in atherosclerosis and clinical significance. Int J Mol Sci. 2015;16:11574–11608.
- Xu Y, Wang M, Xie Y, et al. Activation of GPR39 with the agonist TC-G 1008 ameliorates ox-LDL-induced attachment of monocytes to endothelial cells. Eur J Pharmacol. 2019;858:172451.
- Muneoka S, Goto M, Kadoshima-Yamaoka K, et al. G protein-coupled receptor 39 plays an anti-inflammatory role by enhancing IL-10 production from macrophages under inflammatory conditions. Eur J Pharmacol. 2018;834:240–245.
- Voelkl J, Tuffaha R, Luong TTD, et al. Zinc inhibits phosphate-induced vascular calcification through TNFAIP3-mediated suppression of NF-kappaB. J Am Soc Nephrol. 2018;29:1636–1648.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408.
- Panjwani N, Mulvihill EE, Longuet C, et al. GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE(-/-) Mice. Endocrinology. 2013;154:127–139.
- Kavurma MM, Rayner KJ, Karunakaran D. The walking dead: macrophage inflammation and death in atherosclerosis. Curr Opin Lipidol. 2017;28:91–98.
- Kim J, Song TJ, Song D, et al. Nonrelevant cerebral atherosclerosis is a strong prognostic factor in acute cerebral infarction. Stroke. 2013;44:2013–2015.
- Jover E, Marin F, Roldan V, et al. Valdes M and Lip GY: atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease. Ann Med. 2013;45:274–290.
- Zhang Y, Qiao B, Gao F, et al. Melatonin protects H9c2 cells against ischemia/reperfusioninduced apoptosis and oxidative stress via activation of the Nrf2 signaling pathway. Mol Med Rep. 2018;18:3497–3505.
- Li YF, Li RS, Samuel SB, et al. Lysophospholipids and their G protein-coupled receptors in atherosclerosis. Front Biosci (Landmark Ed). 2016;21:70–88.
- Yu H, Rimbert A, Palmer AE, et al. GPR146 deficiency protects against hypercholesterolemia and atherosclerosis. Cell. 2019;179:1276–1288 e1214.
- Groh L, Keating ST, Joosten LAB. Monocyte and macrophage immunometabolism in atherosclerosis. Semin Immunopathol. 2018;40:203–214.
- Jing W, Sun W, Zhang N, et al. The protective effects of the GPR39 agonist TC-G 1008 against TNF-alpha-induced inflammation in human fibroblast-like synoviocytes (FLSs). Eur J Pharmacol. 2019;865:172663.
- Li HL, Wang AB, Zhang R, et al. A20 inhibits oxidized low-density lipoprotein-induced apoptosis through negative Fas/Fas ligand-dependent activation of caspase-8 and mitochondrial pathways in murine RAW264.7 macrophages. J Cell Physiol. 2006;208:307–318.
- Maguire EM. Foam cell formation: a new target for fighting atherosclerosis and cardiovascular disease. Vascul Pharmacol. 2019;112:54–71.
- Yu XH, Fu YC, Zhang DW. Foam cells in atherosclerosis. Clin Chim Acta. 2013;424:245–252.
- Kolodziejski PA, Pruszynska-Oszmalek E, Sassek M, et al. Changes in obestatin gene and GPR39 receptor expression in peripheral tissues of rat models of obesity, type 1 and type 2 diabetes. J Diabetes. 2017;9:353–361.